EUVIMEDEUVIMED entdecken
Crossref

In Brief: New Warnings for Carbidopa/Levodopa Products

The Medical Letter on Drugs and Therapeutics · 27.04.2026 · 68 (1753) · 72-72

DOI: 10.58347/tml.2026.1753b ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 27.04.2026.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA has required that the labels of all carbidopa/levodopa-containing products (Crexont, Dhivy, Duopa, Rytary, Sinemet, Sinemet CR, Stalevo, Vyalev) include a warning about the risk of vitamin B6 (pyridoxine) deficiency and vitamin B6 deficiency-related seizures associated with their use. The combination of carbidopa/levodopa is the most effective treatment for the motor symptoms of Parkinson's disease and recent evidence favors its early use.

Schlagwörter

Stichwörter der Autor:innen

CrexontDhivyDuopaParkinson's diseaseRytarySinemetStalevoVyalevadverse effectscarbidopa/levodopadrug safetypyridoxinesafety

Zitieren

APA

(2026). In Brief: New Warnings for Carbidopa/Levodopa Products. The Medical Letter on Drugs and Therapeutics, 68(1753), 72-72. https://doi.org/10.58347/tml.2026.1753b

Vancouver

In Brief: New Warnings for Carbidopa/Levodopa Products. The Medical Letter on Drugs and Therapeutics. 2026;68(1753):72-72. doi:10.58347/tml.2026.1753b

BibTeX
@article{euvimed2026,
  title = {In Brief: New Warnings for Carbidopa/Levodopa Products},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2026},
  volume = {68},
  number = {1753},
  pages = {72--72},
  doi = {10.58347/tml.2026.1753b}
}
Kostenlos starten →